Proxied therapeutic inhibition on sclerostin and atrial fibrillation risk

Commun Med (Lond). 2026 May 30. doi: 10.1038/s43856-026-01694-4. Online ahead of print.ABSTRACTBACKGROUND: Pharmacological inhibition of sclerostin (SOST) is clinically applied to treat osteoporosis. However, large-scale randomized controlled trials have reported conflicting findings regarding the c

Y Yu Qian

Menopause and vascular endothelial health: Is it all about the oestrogen?

Exp Physiol. 2026 May 30. doi: 10.1113/EP092848. Online ahead of print.ABSTRACTCardiovascular disease (CVD) is a leading cause of mortality in women, and CVD risk is accelerated during the menopause transition. This acceleration has traditionally been attributed to the hallmark decline in oestradiol

V Virginia R Nuckols

Discharge medical treatment implementation and predictors of a successful decongestion in patients with acute heart failure: first data from the BRING-UP 3 Heart Failure Study

Eur J Intern Med. 2026 May 8:106860. doi: 10.1016/j.ejim.2026.106860. Online ahead of print.ABSTRACTBACKGROUND: Real-world uptake of guideline-directed medical therapy (GDMT) at hospital discharge and clinical predictors of complete decongestion in acute heart failure (AHF) populations remain insuff

B BRING-UP 3 Heart Failure Investigators

Retinal vein occlusion

Handb Clin Neurol. 2026;218:271-287. doi: 10.1016/B978-0-443-22212-2.00014-8.ABSTRACTRetinal vein occlusion (RVO) is the second most common retinal vascular disease after diabetic retinopathy and can result in significant vision loss and ocular morbidity. Vision loss may result from hemorrhages, mac

T Tahreem A Mir